Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Inclusion Criteria: * Clinically confirmed diagnosis of CRSwNP * Nasal polyp score (NPS) ≥ 4 out of a maximum score for both nostrils (with at least a score of 1 for each nostril). * 22 Item Sino-Nasal Outcome Test (SNOT-22) score \> 15. * Presence of at least two of the following symptoms prior to screening: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; reduction or loss of smell * Body mass index (BMI) of 18 to 42 kg/m\^2 (inclusive) and total body weight \> 50 kg (110 lb). BMI=weight (kg)/(height \[m\^2\]). Exclusion Criteria: * Use of investigational drugs or prohibited therapy for this study within 8 weeks before screening or 5 half-lives, whichever is longer. * Have experienced severe life threatening anaphylactic reactions. * Participation in any interventional study for the treatment of CRSwNP in the 3 months before screening. * If female, is pregnant or lactating, or intend to become pregnant during the study period. * History (or suspected history) of alcohol or substance abuse. * Current smokers or former smokers with a smoking history of ≥ 10 pack years. If a patient has less than 10 pack years smoking history, he or she should have quit smoking at least 2 months before screening to enroll in the study. Note: Other protocol defined Inclusion/Exclusion criteria may apply.